Close Menu

This article was updated to note that the Decipher test is sold by Decipher Biosciences, not GenomeDx Biosciences. 

NEW YORK – The National Comprehensive Cancer Network has updated prostate cancer guidelines to recommend biomarker testing for patients with unfavorable intermediate or high risk for aggressive disease.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.